Name | Blebbistatin |
Description | Blebbistatin ((±)-Blebbistatin) is a non-muscle myosin II (NMII)-selective and non-muscle myosin heavy chain 9 (MYH9)-specific inhibitor that promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, while preserving the integrity of cell junctions and barrier function. |
In vitro | Blebbistatin is a cell-permeable non-muscle myosin II ATPases inhibitor with an IC50 range of 2 μM. |
In vivo | METHODS: Blebbistatin ((±)-Blebbistatin) (10, 20, 40 mg/kg, intraperitoneal injection, once every two days, 4 weeks) was administered to NCl-H460 model nude mice, and the changes in tumors in the mice were observed.
RESULTS The inhibition rates of Blebbistatin ((±)-Blebbistatin) on xenograft tumor weight were 23.4%, 40.2%, and 83.4%, respectively. [1] |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 23 mg/mL (78.67 mM), Sonication is recommended.
|
Keywords | Inhibitor | Myosin | inhibit | Blebbistatin |
Inhibitors Related | Tirofiban hydrochloride monohydrate | Sodium oleate | Fenbufen | trans-Aconitic acid | Phlorizin | Chlorpropamide | Vonoprazan fumarate | Esomeprazole Magnesium | Revaprazan hydrochloride | Oleic acid | Esomeprazole Sodium | Trichlormethiazide |
Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Mitochondria-Targeted Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Ion Channel Targeted Library | Human Metabolite Library |